During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Jonathan L. Kaufman, Emory University School of Medicine, Atlanta, US. We asked, What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) relapsed/ refractory multiple myeloma (RRMM)?

In this interview, Jonathan Kaufman discusses how the addition of venetoclax to combination carfilzomib + dexamethasone (Kd) can improve outcomes in patients with t(11;14). Kaufman highlights the influence of Kd on the sensitivity of myeloma cells to B-cell lymphoma 2 (BCL-2) inhibition, and how this can improve the potency of BCL-2 inhibitors such as venetoclax.